NCT00075933已完成1 期
A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)4 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2003年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 4
研究概览
简要总结
ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT).
ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
- •ECOG performance status greater than or equal to 1
- •Life expectancy greater than three months
- •Acceptable pretreatment clinical laboratory results
排除标准
- •Subjects who have had chemotherapy or radiotherapy within 4 weeks
- •Subjects receiving any other investigational agents
- •Subjects with known untreated brain metastases
- •Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
- •Subjects with uncontrolled intercurrent illnesses
- •Pregnant women
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
KRN5500 in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00017238National Cancer Institute (NCI)40
已完成
1 期
Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With ChloroquineMalariaNCT00323375Tulane University Health Sciences Center122
终止
2 期
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)Carcinoma, Non-Small-Cell LungNCT00290550Merck Sharp & Dohme LLC22
终止
1 期
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellEsophageal Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckNCT05462873Novartis Pharmaceuticals30
已完成
1 期
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514Cancer CachexiaNCT05264038Oncocross Australia Pty Ltd.23